Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
News about QIAGEN N.V. (QGEN) centers on its role as a Netherlands-based Sample to Insight company serving life sciences and molecular diagnostics customers worldwide. This news feed aggregates corporate announcements, product updates, regulatory milestones and financial communications directly related to QGEN.
Readers can follow updates on QIAGEN’s five growth pillars: Sample technologies, QIAstat-Dx syndromic testing, QIAcuity digital PCR, QIAGEN Digital Insights (QDI) bioinformatics and QuantiFERON latent tuberculosis testing. Company news often highlights launches and enhancements of automation systems such as QIAcube Connect, QIAsymphony Connect, QIAsprint, QIAmini and EZ2 Connect Fx, as well as new kits like the EZ2 DNA Investigator Sep&Prep Kit for forensic applications.
Regulatory and clinical diagnostics news includes items such as CE-IVDR certification for QIAstat-Dx panels in Europe, U.S. FDA clearance for QIAstat-Dx Rise, and expansions of test menus for respiratory, gastrointestinal and central nervous system infections. These announcements show how QIAGEN positions its platforms in infectious disease and syndromic testing.
Investors and analysts can also track financial and capital markets developments, including quarterly earnings releases furnished on Form 6-K, outlook updates, and capital return actions such as synthetic share repurchase plans that combine direct capital repayments with reverse stock splits. Strategic moves, for example the agreement to acquire Parse Biosciences to expand into single-cell analysis, are another recurring theme in QGEN news.
For users interested in precision oncology, bioinformatics and AI-enabled solutions, QIAGEN’s news includes information on partnerships, new software capabilities within QDI, and integrated Sample to Insight workflows. Bookmark this page to access an organized stream of QGEN-related announcements spanning products, diagnostics, automation, bioinformatics and investor communications.
QIAGEN has acquired a 96% stake in BLIRT SA, enhancing its capabilities in recombinant enzymes and molecular biology reagents. BLIRT, based in Poland, specializes in producing essential proteins and enzymes for diagnostics, generating under $10 million in sales in 2021. This acquisition aims to bolster QIAGEN's sample technologies business, expand global production, and enhance R&D capacities. The deal is expected to close in Q2 2022 and will not materially impact QIAGEN's financial outlook for the year, as previously stated.
QIAGEN N.V. announced Dr. Eva Pisa as a proposed new member of the Supervisory Board, enhancing leadership in the Life Science and Molecular Diagnostics sectors. All current board members will stand for re-election at the Annual General Meeting scheduled for June 23, 2022, in Venlo, Netherlands. Dr. Pisa's experience includes roles at Sangtec Molecular Diagnostics and Roche Diagnostics, offering valuable insights into health diagnostics. This strategic move aligns with QIAGEN's commitment to value creation for stakeholders in the Life Science and Molecular Diagnostics markets.
QIAGEN has announced the availability of its NeuMoDx HSV 1/2 Quant Assay for detecting herpes simplex virus type 1 and 2, following its CE-IVD certification. This assay enhances QIAGEN's offerings in viral load monitoring, particularly for immunocompromised patients, now totaling 15 CE-IVD assays for the NeuMoDx systems. The new assay is critical for organ transplant patients, addressing significant mortality risks from herpesvirus infections. QIAGEN also plans to launch additional assays in 2022, including tests for HHV-6 and reformulated EBV assays.
QIAGEN N.V. reported a strong Q1 2022, with net sales growing 11% to $628.4 million, exceeding the forecast of at least 7% growth. The company experienced a 14% rise in non-COVID sales and 18% growth in COVID-related products. Adjusted diluted EPS rose to $0.80, surpassing the expected $0.72. QIAGEN has raised its full-year net sales outlook to at least $2.12 billion and reaffirmed double-digit growth in non-COVID product lines. Despite anticipated sales declines in COVID products due to market volatility, QIAGEN remains committed to ongoing investments in its growth pillars.
QIAGEN N.V. (NYSE: QGEN) announced it will release its first quarter 2022 results on April 27 at 22:05 Frankfurt time. A conference call will follow on April 28 at 16:00 Frankfurt time, hosted by CEO Thierry Bernard and CFO Roland Sackers. Investors can join via phone or access an audio webcast. This call will provide insights into the company's financial performance and strategic developments.
On World TB Day, QIAGEN announced its QuantiFERON blood test has screened over 100 million patients for tuberculosis (TB), solidifying its status as the gold standard in TB testing. This test, utilized in over 130 countries, offers a more accurate alternative to traditional skin tests. With accurate testing, it aims to prevent 1.5 million TB-related deaths annually. QIAGEN is also expanding its QuantiFERON franchise and has introduced a portable version for low-resource settings, further enhancing its impact on TB diagnosis and control.
QIAGEN N.V. (NYSE: QGEN) has filed its annual report, including audited financial statements for the year ended December 31, 2021, with the U.S. Securities and Exchange Commission. Shareholders can request printed copies free of charge. QIAGEN specializes in providing Sample to Insight solutions, serving over 500,000 customers worldwide in fields such as Molecular Diagnostics, Applied Testing, Pharma, and Academia. The company employs over 6,000 staff across 35 locations. For further details, the report is accessible on QIAGEN’s website.
QIAGEN N.V. (NYSE: QGEN) reported a 2% increase in Q4 2021 net sales, reaching $582 million, significantly above the expected decline. The full-year net sales surged 20% to $2.25 billion, with adjusted diluted EPS rising 23% to $2.65. The non-COVID product sales grew by 22% (CER), exceeding the 20% target. QIAGEN anticipates 2022 net sales of at least $2.07 billion, expecting double-digit growth in non-COVID products. Strong cash flow metrics were highlighted, with operating cash flow rising 40% to $639 million and free cash flow up 38% to $449 million.
QIAGEN announced that its QuantiFERON-TB Gold Plus (QFT-Plus) has received approval from China's NMPA for diagnosing active tuberculosis (TB). This approval enhances QFT-Plus's established market position following previous regulatory success in the U.S. The WHO has also recommended QFT-Plus as the modern gold standard for TB detection, promoting its use along with the new QIAreach QFT in epidemiological research. The QFT-Plus test, which has seen over 1.5 million tests in China since 2013, is noted for easier scalability and accuracy, especially for immunocompromised patients.
QIAGEN (NYSE: QGEN) has completed a U.S. government contract to supply QIAcuity digital PCR systems for wastewater surveillance of SARS-CoV-2. Over 35 systems have been shipped to public health labs, with 70% of U.S. states now utilizing this technology. The QIAcuity platform provides rapid results within two hours, enhancing pandemic response capabilities. This initiative supports public health authorities in monitoring infection spread and mutations, offering crucial near-real-time data. QIAGEN aims to continue aiding public health efforts globally as testing shifts towards infectious disease monitoring.